机构：[a]Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China[b]Department of Oncology, Guangdong Second Provincial Traditional Chinese Medicine Hospital, Guangzhou 510095, China大德路总院肿瘤科广东省中医院[c]Department of Vascular Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China中山大学附属第一医院[d]Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China中山大学附属第一医院[e]Department of Sports Medicine, Peking University Shenzhen Hospital, Shenzhen 518036, China北京大学深圳医院深圳市康宁医院深圳医学信息中心[f]Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China[g]Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China[h]Guangdong Provincial Key Laboratory of Molecular Tumour Pathology, Guangzhou 510515, China
Although CXCR4 and CD133 have been implicated in the metastatic process of malignant tumors, the clinicopathological significance of their expression in human colon cancer is not fully understood. The present study aimed to examine the expression of the CXCR4 and CD133 proteins in cases of stage II or III colon cancer and the related lymph nodes and to investigate the clinical and prognostic significance of these proteins in colon cancer. Immunohistochemical analysis was performed to examine CXCR4 and CD133 protein expression in paraffin-embedded stage II or III primary colon cancer tissues and matched lymph nodes. The correlation between the expression of the two proteins and clinicopathological parameters and the patient 5-year survival was analyzed. CXCR4 expression was detected in 74 of the 125 tumors (59.2%) and CD133 expression was detected in 45 (36.0%). The co-expression of CXCR4 and CD133 (both CXCR4 and CD133 were positive) was detected in 29 of the 125 tumors (23.2%). Compared with the other combinations, the co-expression of the CXCR4 and CD133 proteins was significantly associated with American Joint Committee on Cancer (AJCC) stage (P=0.029) and lymph node status (P=0.020). Log-rank analysis revealed that AJCC stage (P=0.014), lymph node status (P=0.011), CXCR4 expression (P=0.023), CD133 expression (P=0.034) and the co-expression of the CXCR4 and CD133 proteins (P=0.003) were significant prognostic indicators for the overall survival of patients. The results of the present study show that the co-expression of the CXCR4 and CD133 proteins is a risk factor for poor overall survival in stage II or III colon cancer patients, indicating that the co-expression of the CXCR4 and CD133 proteins contributes to the progression of colon cancer.
基金：
Guangdong Natural Science FoundationNational Natural Science Foundation of Guangdong Province [10251051501000008]
第一作者机构：[a]Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China[b]Department of Oncology, Guangdong Second Provincial Traditional Chinese Medicine Hospital, Guangzhou 510095, China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang N.-H,Li J,Li Y,et al.Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients[J].EXPERIMENTAL AND THERAPEUTIC MEDICINE.2012,3(6):973-982.doi:10.3892/etm.2012.527.
APA：
Zhang, N.-H,Li, J,Li, Y,Zhang, X.-T,Liao, W.-T...&Luo, R.-C.(2012).Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients.EXPERIMENTAL AND THERAPEUTIC MEDICINE,3,(6)
MLA：
Zhang, N.-H,et al."Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients".EXPERIMENTAL AND THERAPEUTIC MEDICINE 3..6(2012):973-982
